Congress Coverage: ASCO 2021 – Focus on Lung Cancer
Expert perspectives and strategic insights on the latest therapeutic developments and translational research in lung cancer treatment.
Faculty Chair
Corey J. Langer, MD, FACP
University of Pennsylvania, Philadelphia, PA, USA
FACULTY MEMBERS
Julie Brahmer, MD
Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA
Enriqueta Felip, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain
Marina Garassino, MD
University of Chicago Medicine, Chicago, Il, USA
David Jablons, MD
University of California San Francisco, San Francisco, CA, USA
Natasha Leighl, MD
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Paul Paik, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Lynette Sholl, MD
Dana-Farber Cancer Institute, Boston, MA, USA
David Spigel, MD
Sarah Cannon Cancer Center, Nashville, TN, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Immunotherapy in Stage I–III NSCLC
- Immunotherapy in Stage IV NSCLC
- EGFR (Common Mutations): Resectable and Metastatic
- EGFR (Exon 20 and Other Uncommon Mutations)
- Oncogenic Fusions
- Oncogenic Mutations
- Other Targets in NSCLC/SCLC
